Möchten Sie immer auf dem neuesten Stand bleiben?

The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery for cardiometabolic diseases (CMDs).

Austin, TX, USA, June 17, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “GLP-1 Receptor Agonist Market Size, Trends and Insights By Product Type...

NEWPORT BEACH, CA, June 05, 2026 (GLOBE NEWSWIRE) -- Whoosh Wellness, a premium physician-guided telehealth wellness platform, today announced its official launch, offering health-conscious adults...

Liver disease is often found late because people have no symptoms. This research shows how using existing NHS blood test data could help change that.

Tokyo, Japan and Cambridge, UK, 09 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a second development milestone under its multi-target...

Jeito Capital, Novo Holdings and other healthcare investors join Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega FundsAdditional capital further supports clinical...

Council brings together leading global scientific and clinical experts in metabolic diseases to guide development of Nxera’s expanding proprietary pipeline Tokyo, Japan and Cambridge, UK, 20...

Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist,...

Austin, TX, USA, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Umbilical Cord Blood Banking Market Size, Trends and Insights By Storage Type...

Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment...